Role for the Epidermal Growth Factor Receptor in Chemotherapy-Induced Alopecia

Kyle J. Bichsel, Navdeep Gogia, Timothy Malouff, Zachary Pena, Eric Forney, Brianna Hammiller, Patrice Watson, Laura A. Hansen

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Treatment of cancer patients with chemotherapeutics like cyclophosphamide often causes alopecia as a result of premature and aberrant catagen. Because the epidermal growth factor receptor (EGFR) signals anagen hair follicles to enter catagen, we hypothesized that EGFR signaling may be involved in cyclophosphamide-induced alopecia. To test this hypothesis, skin-targeted Egfr mutant mice were generated by crossing floxed Egfr and Keratin 14 promoter-driven Cre recombinase mice. Cyclophosphamide treatment of control mice resulted in alopecia while Egfr mutant skin was resistant to cyclophosphamide-induced alopecia. Egfr mutant skin entered catagen normally, as indicated by dermal papilla condensation and decreased follicular proliferation, but did not progress to telogen as did Egfr wild type follicles. Egfr mutant follicles responded with less proliferation, apoptosis, and fewer p53-positive cells after cyclophosphamide. Treatment of control mice with the EGFR inhibitors erlotinib or gefitinib similarly suppressed alopecia and catagen progression by cyclophosphamide. Secondary analysis of clinical trials utilizing EGFR-targeted therapies and alopecia-inducing chemotherapy also revealed evidence for involvement of EGFR in chemotherapy-induced alopecia. Taken together, our results demonstrated the involvement of EGFR signaling in chemotherapy-induced alopecia, which will help in the design of novel therapeutic regimens to minimize chemotherapy-induced alopecia.

Original languageEnglish
Article numbere69368
JournalPLoS One
Volume8
Issue number7
DOIs
StatePublished - Jul 19 2013

Fingerprint

Chemotherapy
alopecia
Alopecia
Epidermal Growth Factor Receptor
Cyclophosphamide
drug therapy
cyclophosphamide
Drug Therapy
Skin
mutants
mice
Keratin-14
skin (animal)
Therapeutics
epidermal growth factor receptors
Condensation
therapeutics
hair follicles
skin tests
Hair Follicle

All Science Journal Classification (ASJC) codes

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Bichsel, K. J., Gogia, N., Malouff, T., Pena, Z., Forney, E., Hammiller, B., ... Hansen, L. A. (2013). Role for the Epidermal Growth Factor Receptor in Chemotherapy-Induced Alopecia. PLoS One, 8(7), [e69368]. https://doi.org/10.1371/journal.pone.0069368

Role for the Epidermal Growth Factor Receptor in Chemotherapy-Induced Alopecia. / Bichsel, Kyle J.; Gogia, Navdeep; Malouff, Timothy; Pena, Zachary; Forney, Eric; Hammiller, Brianna; Watson, Patrice; Hansen, Laura A.

In: PLoS One, Vol. 8, No. 7, e69368, 19.07.2013.

Research output: Contribution to journalArticle

Bichsel, KJ, Gogia, N, Malouff, T, Pena, Z, Forney, E, Hammiller, B, Watson, P & Hansen, LA 2013, 'Role for the Epidermal Growth Factor Receptor in Chemotherapy-Induced Alopecia', PLoS One, vol. 8, no. 7, e69368. https://doi.org/10.1371/journal.pone.0069368
Bichsel KJ, Gogia N, Malouff T, Pena Z, Forney E, Hammiller B et al. Role for the Epidermal Growth Factor Receptor in Chemotherapy-Induced Alopecia. PLoS One. 2013 Jul 19;8(7). e69368. https://doi.org/10.1371/journal.pone.0069368
Bichsel, Kyle J. ; Gogia, Navdeep ; Malouff, Timothy ; Pena, Zachary ; Forney, Eric ; Hammiller, Brianna ; Watson, Patrice ; Hansen, Laura A. / Role for the Epidermal Growth Factor Receptor in Chemotherapy-Induced Alopecia. In: PLoS One. 2013 ; Vol. 8, No. 7.
@article{5cb76fc7c241419d983aafc8dce4e7e6,
title = "Role for the Epidermal Growth Factor Receptor in Chemotherapy-Induced Alopecia",
abstract = "Treatment of cancer patients with chemotherapeutics like cyclophosphamide often causes alopecia as a result of premature and aberrant catagen. Because the epidermal growth factor receptor (EGFR) signals anagen hair follicles to enter catagen, we hypothesized that EGFR signaling may be involved in cyclophosphamide-induced alopecia. To test this hypothesis, skin-targeted Egfr mutant mice were generated by crossing floxed Egfr and Keratin 14 promoter-driven Cre recombinase mice. Cyclophosphamide treatment of control mice resulted in alopecia while Egfr mutant skin was resistant to cyclophosphamide-induced alopecia. Egfr mutant skin entered catagen normally, as indicated by dermal papilla condensation and decreased follicular proliferation, but did not progress to telogen as did Egfr wild type follicles. Egfr mutant follicles responded with less proliferation, apoptosis, and fewer p53-positive cells after cyclophosphamide. Treatment of control mice with the EGFR inhibitors erlotinib or gefitinib similarly suppressed alopecia and catagen progression by cyclophosphamide. Secondary analysis of clinical trials utilizing EGFR-targeted therapies and alopecia-inducing chemotherapy also revealed evidence for involvement of EGFR in chemotherapy-induced alopecia. Taken together, our results demonstrated the involvement of EGFR signaling in chemotherapy-induced alopecia, which will help in the design of novel therapeutic regimens to minimize chemotherapy-induced alopecia.",
author = "Bichsel, {Kyle J.} and Navdeep Gogia and Timothy Malouff and Zachary Pena and Eric Forney and Brianna Hammiller and Patrice Watson and Hansen, {Laura A.}",
year = "2013",
month = "7",
day = "19",
doi = "10.1371/journal.pone.0069368",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Role for the Epidermal Growth Factor Receptor in Chemotherapy-Induced Alopecia

AU - Bichsel, Kyle J.

AU - Gogia, Navdeep

AU - Malouff, Timothy

AU - Pena, Zachary

AU - Forney, Eric

AU - Hammiller, Brianna

AU - Watson, Patrice

AU - Hansen, Laura A.

PY - 2013/7/19

Y1 - 2013/7/19

N2 - Treatment of cancer patients with chemotherapeutics like cyclophosphamide often causes alopecia as a result of premature and aberrant catagen. Because the epidermal growth factor receptor (EGFR) signals anagen hair follicles to enter catagen, we hypothesized that EGFR signaling may be involved in cyclophosphamide-induced alopecia. To test this hypothesis, skin-targeted Egfr mutant mice were generated by crossing floxed Egfr and Keratin 14 promoter-driven Cre recombinase mice. Cyclophosphamide treatment of control mice resulted in alopecia while Egfr mutant skin was resistant to cyclophosphamide-induced alopecia. Egfr mutant skin entered catagen normally, as indicated by dermal papilla condensation and decreased follicular proliferation, but did not progress to telogen as did Egfr wild type follicles. Egfr mutant follicles responded with less proliferation, apoptosis, and fewer p53-positive cells after cyclophosphamide. Treatment of control mice with the EGFR inhibitors erlotinib or gefitinib similarly suppressed alopecia and catagen progression by cyclophosphamide. Secondary analysis of clinical trials utilizing EGFR-targeted therapies and alopecia-inducing chemotherapy also revealed evidence for involvement of EGFR in chemotherapy-induced alopecia. Taken together, our results demonstrated the involvement of EGFR signaling in chemotherapy-induced alopecia, which will help in the design of novel therapeutic regimens to minimize chemotherapy-induced alopecia.

AB - Treatment of cancer patients with chemotherapeutics like cyclophosphamide often causes alopecia as a result of premature and aberrant catagen. Because the epidermal growth factor receptor (EGFR) signals anagen hair follicles to enter catagen, we hypothesized that EGFR signaling may be involved in cyclophosphamide-induced alopecia. To test this hypothesis, skin-targeted Egfr mutant mice were generated by crossing floxed Egfr and Keratin 14 promoter-driven Cre recombinase mice. Cyclophosphamide treatment of control mice resulted in alopecia while Egfr mutant skin was resistant to cyclophosphamide-induced alopecia. Egfr mutant skin entered catagen normally, as indicated by dermal papilla condensation and decreased follicular proliferation, but did not progress to telogen as did Egfr wild type follicles. Egfr mutant follicles responded with less proliferation, apoptosis, and fewer p53-positive cells after cyclophosphamide. Treatment of control mice with the EGFR inhibitors erlotinib or gefitinib similarly suppressed alopecia and catagen progression by cyclophosphamide. Secondary analysis of clinical trials utilizing EGFR-targeted therapies and alopecia-inducing chemotherapy also revealed evidence for involvement of EGFR in chemotherapy-induced alopecia. Taken together, our results demonstrated the involvement of EGFR signaling in chemotherapy-induced alopecia, which will help in the design of novel therapeutic regimens to minimize chemotherapy-induced alopecia.

UR - http://www.scopus.com/inward/record.url?scp=84880436631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880436631&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0069368

DO - 10.1371/journal.pone.0069368

M3 - Article

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e69368

ER -